# US 2006/0154886 A1 · Regulatory elements in the 5' region of the VR1 gene

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0154886 A1
- Document ID: US20060154886A1
- Status: Published application
- Kind: A1
- Application number: 11/148,303
- Filed: 2005-06-09
- Published: 2006-07-13
- Earliest claimed: 2002-12-09
- Assignees: Gruenenthal GmbH
- Inventors: Eberhard Weihe; Annette Bieller; Martin Schaefer
- Web page: https://patentgrep.com/patent/US20060154886A1

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A nucleic acid comprising a sequence section which modulates the expression of the VR1 receptor, a vector containing this nucleic acid and a host cell which is transformed with this vector are disclosed, along with related pharmaceutical formulations. Methods for modulating the expression of the VR1 receptor and the use of the nucleic acid or vector for alleviating, preventing or treating pain and for treating sensibility disorders associated with the VR1 receptor are also provided.

## Claims

### Claim 1

A nucleic acid comprising a sequence section which contains at least one region which modulates the expression of the VR1 receptor, said sequence section having a sequence selected from the group consisting of: FIG. 3 (SEQ ID NO: 7); FIG. 4 (SEQ ID NO: 8); GenBank Accession Number AL670399, positions 221931 to 223344; GenBank Accession Number AL663116, positions 31673 to 36359; GenBank Accession Number AF168787, positions 44731 to 43231; and GenBank Accession Number AF168787, positions 36616 to 33151, or a homologous derivative, allele or fragment thereof which modulates the expression of the VR1 receptor, or a sequence which hybridizes with one of the foregoing under standard conditions.

### Claim 2 (depends on 1)

A nucleic acid according to claim 1, wherein the region which modulates the expression of the VR1 receptor comprises a transcription factor binding site.

### Claim 3 (depends on 2)

A nucleic acid according to claim 2, wherein the sequence section comprises one or more binding motifs for a transcription factor selected from the group consisting of MZF1, NFkappaB, GATA 1/2/3, IK 2, NFAT, AP4, SRY, SOX5, CP2, cMyb, SREBP1, deltaEF1, MyoD, GKLF, NRF2, NF1, CETS1P54, NFY TH1E47, RORA1, GFI1, AP1, GATA 1, TCF11, 4255), IK2/1, Brn2, S8, HNF3B and HFH2.

### Claim 4 (depends on 1)

A nucleic acid according to claim 1, wherein said nucleic acid is a double-stranded DNA molecule.

### Claim 5 (depends on 1)

A nucleic acid according to claim 1, wherein said nucleic acid contains at least one of modified internucleotide bonds or modified nucleobases.

### Claim 6 (depends on 1)

A nucleic acid according to claim 1, wherein said nucleic acid comprises about 13 to about 65 nucleotides or base pairs.

### Claim 7 (depends on 1)

A nucleic acid according to claim 1, wherein the sequence section comprises the sequence shown in FIG. 3 (SEQ ID NO: 7) or a derivative, allele or fragment thereof which modulates the expression of the VR1 receptor, or a sequence which hybridizes thereto under standard conditions.

### Claim 8 (depends on 1)

A nucleic acid according to claim 1, wherein the sequence section comprises a sequence which hybridizes under stringent conditions to the sequence shown in FIG. 3 (SEQ ID NO: 7) or a derivative, allele or fragment thereof which modulates the expression of the VR1 receptor.

### Claim 9 (depends on 1)

A nucleic acid according to claim 1, wherein the sequence section comprises the sequence shown in FIG. 4 (SEQ ID NO: 8) or a derivative, allele or fragment thereof which modulates the expression of the VR1 receptor, or a sequence which hybridizes thereto under standard conditions.

### Claim 10 (depends on 1)

A nucleic acid according to claim 1, wherein the sequence section comprises a sequence which hybridizes under stringent conditions to the sequence shown in FIG. 4 (SEQ ID NO: 8) or a derivative, allele or fragment thereof which modulates the expression of the VR1 receptor.

### Claim 11 (depends on 1)

A nucleic acid according to claim 1, wherein the sequence section comprises the nucleotides of positions 1 to 1423 of the sequence shown in FIG. 3 (SEQ ID NO: 7) or a derivative, allele or fragment thereof which modulates the expression of the VR1 receptor, or a sequence which hybridizes thereto under standard conditions.

### Claim 12 (depends on 1)

A nucleic acid according to claim 1, wherein the sequence section comprises the nucleotides of positions 1 to 4549 of the sequence shown in FIG. 4 (SEQ ID NO: 8) or a derivative, allele or fragment thereof which modulates the expression of the VR1 receptor, or a sequence which hybridizes thereto under standard conditions.

### Claim 13 (depends on 1)

A nucleic acid according to claim 1, wherein the sequence section comprises the nucleotides of positions 4060 to 4219 of the sequence shown in FIG. 4 (SEQ ID NO: 8) or a derivative, allele or fragment thereof which modulates the expression of the VR1 receptor, or a sequence which hybridizes thereto under standard conditions.

### Claim 14 (depends on 1)

A vector containing a nucleic acid according to claim 1.

### Claim 15 (depends on 14)

A host cell which is transformed with the vector according to claim 14.

### Claim 16 (depends on 15)

A host cell according to claim 15, wherein the host cell is a human germ cell or a human embryonic stem cell.

### Claim 17 (depends on 15)

A host cell according to claim 15, wherein the host cell is not a human germ cell or a human embryonic stem cell.

### Claim 18 (depends on 15)

A host cell according to claim 15, wherein the host cell is a mammalian cell.

### Claim 19 (depends on 15)

A host cell according to claim 15, wherein the host cell is a human cell.

### Claim 20 (depends on 1)

A method for modulating the expression of a VR1 receptor comprising: introducing a nucleic acid according to claim 1 into a cell containing a VR1 gene.

### Claim 21 (depends on 14)

A method for modulating the expression of a VR1 receptor comprising: introducing a vector according to claim 14 into a cell containing a VR1 gene.

### Claim 22 (depends on 1)

A pharmaceutical formulation comprising a nucleic acid according to claim 1 and a pharmaceutically acceptable carrier or adjuvant.

### Claim 23 (depends on 14)

A pharmaceutical formulation comprising a vector according to claim 14 and a pharmaceutically acceptable carrier or adjuvant.

### Claim 24 (depends on 15)

A pharmaceutical formulation comprising a host cell according to claim 15 and a pharmaceutically acceptable carrier or adjuvant.

### Claim 25 (depends on 1)

A method of alleviating pain in a mammal, said method comprising administering to said mammal an effective pain alleviating amount of a nucleic acid according to claim 1.

### Claim 26 (depends on 14)

A method of alleviating pain in a mammal, said method comprising administering to said mammal an effective pain alleviating amount of a vector according to claim 14.

### Claim 27 (depends on 1)

A method of treating a sensibility disorder associated with the activity of the VR1 receptor in a mammal, said method comprising administering to said mammal an effective amount of a nucleic acid according to claim 1.

### Claim 28 (depends on 27)

The method of claim 27, wherein the sensibility disorder is an analgesia, hypalgesia or hyperalgesia.

### Claim 29 (depends on 14)

A method of treating sensibility disorders associated with the activity of the VR1 receptor in a mammal, said method comprising administering to said mammal an effective amount of vector according to claim 14.

### Claim 30 (depends on 29)

The method of claim 29, wherein the sensibility disorder is an analgesia, hypalgesia or hyperalgesia.
